Live Analyst Rating Changes 24956 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Jasper Hellweg
ARG

Jasper Hellweg

Wall Street Analyst
★★★☆☆
#1298
on 13Foresight · ranked by our own returns
63%
Success Rate
+7.1%
Average Return
32 of 51 calls profitable · -4.7% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 63% of Jasper Hellweg's ratings turned a profit when each position was held for 1 year — averaging +7.1% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

16 Buy 9 Hold 0 Sell
Jasper's Stock Coverage 41 ratings · 2026-08-15
Company Date Position Consensus Price Target 1-Yr Return vs S&P 500
MRK
Merck & Company
Aug 10, 2026 BUY Strong Buy
-4.6% avg upside
43 analysts
$145.00
6.69% Upside
+3.8% ·
NVO
Novo Nordisk
Aug 07, 2026 HOLD Buy
+152.6% avg upside
26 analysts
-1.8% ·
BMY
Bristol-Myers Squibb
Aug 04, 2026 BUY Buy
-4.7% avg upside
42 analysts
$75.00
17.53% Upside
-3.4% ·
NVS
Novartis
Jul 24, 2026 BUY Buy
-11.5% avg upside
24 analysts
$170.00
12.58% Upside
-2.7% ·
BIIB
Biogen
Jul 10, 2026 HOLD Strong Buy
+21.0% avg upside
52 analysts
+5.4% ·
CH:ALC
Alcon
Jul 01, 2026 BUY Strong Buy
+17.9% avg upside
35 analysts
$68.81
13.41% Upside
+8.0% ·
ELAN
Elanco Animal Health
Jun 23, 2026 BUY Strong Buy
+34.8% avg upside
18 analysts
+2.1% ·
GSK
GlaxoSmithKline
Jun 08, 2026 BUY Hold
-11.7% avg upside
19 analysts
+2.8% ·
ZTS
Zoetis
May 26, 2026 HOLD Buy
+61.0% avg upside
23 analysts
-0.9% ·
ABBV
AbbVie
May 13, 2026 BUY Strong Buy
-3.6% avg upside
46 analysts
$250.00
0.21% Upside
+20.5% ·
RHHBY
Roche Holding
Apr 06, 2026 BUY Buy
+111.5% avg upside
14 analysts
$55.00
0.87% Upside
+11.5% ·
UTHR
United Therapeutics
Mar 03, 2026 BUY Buy
-13.9% avg upside
26 analysts
$560.00
12.05% Upside
+0.2% ·
MRNA
Moderna
Jan 13, 2026 HOLD Hold
+12.0% avg upside
38 analysts
+59.9% ·
REGN
Regeneron
Jun 30, 2025 HOLD Strong Buy
-2.5% avg upside
58 analysts
+19.4% ·
GILD
Gilead Sciences
May 05, 2025 BUY Strong Buy
-14.0% avg upside
66 analysts
$120.00
13.24% Downside
+33.3% ·
ILMN
Illumina
Mar 28, 2025 BUY Buy
-8.2% avg upside
31 analysts
$100.00
47.63% Downside
+47.1% ·
BAX
Baxter International
Feb 24, 2025 BUY Buy
+25.0% avg upside
23 analysts
$40.00
49.57% Upside
-40.1% ·
TEVA
Teva Pharmaceutical
Jan 30, 2025 BUY Buy
-17.7% avg upside
39 analysts
$20.00
45.54% Downside
+91.0% ·
LLY
Eli Lilly & Co
Jan 22, 2025 BUY Strong Buy
-12.1% avg upside
48 analysts
+45.3% ·
VTRS
Viatris
Jan 06, 2025 HOLD Buy
+45.1% avg upside
21 analysts
+9.0% ·
AMGN
Amgen
Aug 20, 2024 BUY Buy
-24.0% avg upside
57 analysts
$360.00
13.23% Downside
-7.5% ·
SNY
Sanofi
Jul 26, 2024 BUY Strong Buy
+68.9% avg upside
20 analysts
$60.00
37.22% Upside
+0.4% ·
VRTX
Vertex Pharmaceuticals
Jun 17, 2024 BUY Strong Buy
-12.3% avg upside
62 analysts
$550.00
8.82% Upside
-6.7% ·
ITGR
Integer Holdings
Apr 29, 2024 BUY Buy
-18.2% avg upside
16 analysts
$125.00
0.12% Downside
+10.8% ·
INCY
Incyte
Apr 25, 2024 BUY Buy
-10.5% avg upside
47 analysts
$70.00
41.76% Downside
+15.6% ·
MDRX
Veradigm
Dec 07, 2022 BUY Buy
+199.9% avg upside
22 analysts
$26.00
430.57% Upside
-31.3% ·
EFX
Equifax
Oct 24, 2022 BUY Strong Buy
+17.9% avg upside
39 analysts
$225.00
24.42% Upside
+8.9% ·
LH
Labcorp Holdings
Sep 19, 2022 HOLD Strong Buy
-14.9% avg upside
37 analysts
+7.9% ·
DGX
Quest Diagnostics
Aug 17, 2022 BUY Buy
-21.8% avg upside
34 analysts
$165.00
29.67% Downside
-2.1% ·
ELV
Elevance Health
Feb 07, 2022 BUY Strong Buy
+12.8% avg upside
33 analysts
$500.00
24.84% Upside
+7.4% ·
IQV
IQVIA Holdings
Sep 10, 2021 BUY Strong Buy
+3.3% avg upside
39 analysts
$290.00
22.61% Upside
-14.3% ·
HCA
HCA Healthcare
Aug 02, 2021 BUY Buy
+0.5% avg upside
36 analysts
$275.00
32.08% Downside
-15.0% ·
BSX
Boston Scientific
Jun 07, 2021 BUY Strong Buy
+30.8% avg upside
38 analysts
$50.00
3.55% Downside
-6.1% ·
EBS
Emergent Biosolutions
May 05, 2021 HOLD Buy
+450.1% avg upside
9 analysts
-47.1% ·
BFH
Bread Financial Holdings
May 03, 2021 BUY Buy
+26.3% avg upside
36 analysts
$135.00
19.02% Upside
-39.9% ·
FISV
Fiserv
Jun 12, 2020 BUY Buy
+71.2% avg upside
50 analysts
$115.00
111.38% Upside
+9.8% ·
PRGO
Perrigo Company
Apr 17, 2020 HOLD Buy
+426.8% avg upside
20 analysts
-18.2% ·
LGND
Ligand Pharma
Mar 24, 2020 HOLD Strong Buy
-7.0% avg upside
15 analysts
+92.9% ·
MAN
ManpowerGroup
Oct 30, 2019 HOLD Buy
+21.6% avg upside
17 analysts
-24.4% ·
PINS
Pinterest
Aug 15, 2019 BUY Strong Buy
+33.8% avg upside
47 analysts
$40.00
66.18% Upside
+8.3% ·
FSLR
First Solar
Aug 31, 2016 HOLD Strong Buy
+2.7% avg upside
50 analysts
+24.2% ·
🔒 36 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Jasper Hellweg — Frequently Asked Questions
How accurate are Jasper Hellweg's stock ratings?
Based on the calls 13Foresight could measure, about 63% of Jasper's ratings were profitable over a one-year hold, with an average return of +7.1% per rating, or -4.7% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Jasper ranked on 13Foresight?
Jasper Hellweg is currently ranked #1298 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Jasper cover?
Jasper most recently has ratings on MRK, NVO, BMY, NVS, BIIB, CH:ALC, ELAN, GSK, ZTS, ABBV, RHHBY, UTHR and 29 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.